In a bid to bolster its ophthalmology portfolio, Astellas has agreed to acquire Iveric Biofor US$40 per share in cash, representing a total equity value of approximately US$5.9 B. The transaction is driven byIveric Bio’s Zimura (avacincaptad pegol) which is currently under FDA review for geographic atrophy secondary to age-related macular degeneration, with approval expected by August 19, 2023. If approved,the new revenue stream may help in compensating Astellas’ declining sales of Xtandi® (enzalutamide) due to its anticipated patent expiration later this decade.